The DOI matches its Crossref record.
Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing
Abstract
The disposition of naltrexone during acute and chronic administration of 100‐mg oral dose was studied in 4 subjects. Following an acute dose the mean (X) peak naltrexone plasma level was 43.6 ± 29.9 ng/ml at 1 hr and for the major biotransformation product, β‐naltrexol, was 87.2 ± 25.0 ng/ml at 2 hr. Twenty‐four hours after the dose the X levels of naltrexone and f3‐naltrexol declined to 2.1 ± 0.47 and 17.6 ± 5.0 ng/ml, respectively. Following chronic administration the X peak plasma levels of naltrexone and β‐naltrexol rose to 46.4 ± 18.5 and 158.4 ± 89.9 ng /ml at 1 hr, but by 24 hr both compounds declined to levels of the same order as in the acute state at 24 hr. Plasma levels of naltrexone and f3‐naltrexol measured 24 hr after the daily doses of naltrexone throughout the study indicated that steady‐state equilibrium was rapidly attained and that there was no accumulation of naltrexone and beta naltrexol in the plasma after chronic treatment on 100 mg oral doses. Biexponential kinetics were observed for naltrexone and β‐naltrexol in the first 24 hr. The half‐life of naltrexone and β‐naltrexol decreased slightly from the acute to the chronic study from 10.3 ± 3.3 to 9.7 ± 1.1 hr and from 12.7 ± 2.6 to 11.4 ± 2.0 hr. The plasma levels of naltrexone declined slowly from 24 through 72 hr from 2.4 to 1.7 ng/ml, with an apparent half‐life of 96 hr. The renal clearance data indicate that naltrexone is partially reabsorbed while beta naltrexol is actively secreted by the kidney. During acute and chronic naltrexone administration the mean fecal excretion was 2.1% and 3.6%, while urinary excretion was 38% and 70% of the dose in a 24‐hr period. Opiate antagonism to 25 mg heroin challenges was nearly complete through 48 hr after naltrexone. At 72 hr the objective responses reappeared to a greater extent than the subjective ones. Correlation coefficient (r) between naltrexone plasma levels and opiate antagonism was 0.91 and between individual half‐life of naltrexone and opiate antagonism it was 0.99.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Garbutt, J. C., Kranzler, H. R., O’Malley, S. S., Gastfriend, D. R., Pettinati, H. M., Silverman, B. L., Loewy, J. W., Ehrich, E. W., & Vivitrex Study Group, F. T. (2005) · JAMA · doi:10.1001/jama.293.13.1617 · Cited by 635
Heroin and cocaine intravenous self-administration in rats: Mediation by separate neural systems
Ettenberg, A., Pettit, H. O., Bloom, F. E., & Koob, G. F. (1982) · Psychopharmacology · doi:10.1007/bf00428151 · Cited by 563
Maintenance Medication for Opiate Addiction: The Foundation of Recovery
Bart, G. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.694598 · Cited by 461
Mello, N. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00274-h · Cited by 392
Gonzalez, J. P., & Brogden, R. N. (1988) · Drugs · doi:10.2165/00003495-198835030-00002 · Cited by 314
Metadata
- Authors
- Verebey, K., Volavka, J., Mule, S. J., & Resnick, R. B.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1976-09
- Volume
- 20
- Issue
- 3
- Pages
- 315-328
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1818115547
- Cited by
- 270
- References
- 0
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing. https://app.cochat.ai/papers/10.1002/cpt1976203315
- The paper
- Verebey, K., Volavka, J., Mule, S. J., & Resnick, R. B. (1976). Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt1976203315
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.